Ensuring American Pharmaceutical Supply Chain Resilience By Filling The Strategic Active Pharmaceutical Ingredients Reserve

The United States produces only about 10 percent by volume of the active pharmaceutical ingredients used in its finished drugs. Expanding the reserve is intended to reduce reliance on concentrated foreign supply chains and support domestic production.

What the order does ​

• Requires a list of about 26 drugs critical to national health and security within 30 days.
• Directs officials to identify available funding and ready the existing Strategic Active Pharmaceutical Ingredients Reserve within 120 days.
• Requires procurement of a six-month supply of active ingredients for the critical drugs, with a preference for domestically manufactured ingredients where possible.
• Requires an updated list of 86 essential medicines and medical countermeasures, plus a plan to stock six months of ingredients for drugs not already covered.
• Requires a proposal and cost estimate for opening a second U.S. reserve repository within one year.

Who it affects ​

• Domestic manufacturers of active pharmaceutical ingredients and essential medicines.
• Federal health, preparedness, budget, economic policy, and homeland security officials.
• Patients who depend on medicines designated as critical or essential.

Context ​

The existing reserve is described as nearly empty, and implementation depends on available funding.